AMENDMENTS

This listing replaces all prior versions and listings of claims in the application.

1. (Currently Amended) A ~~stable~~ liquid medical formulation (A) that consists of ~~comprises~~ a therapeutically effective amount of an antibody against CD40, sorbitol as isotonizing agent, a polysorbate as surfactant and glutamate as ~~sole~~ buffer and (B) that has a pH between 4.0 and 6.0.

2. (Currently Amended) The ~~stable~~ liquid medical formulation according to claim 1, wherein the concentration of the buffer is between 1 mM and 50 mM.

3-6. (Canceled)

7. (Currently Amended) The ~~stable~~ liquid medical formulation according to claim 1, having an osmotic pressure between 250 mOsm and 350 mOsm.

8. (Canceled)

9. (Currently Amended) The ~~stable~~ liquid medical formulation according to claim 1, wherein the surfactant is polysorbate 80.

10. (Currently Amended) The ~~stable~~ liquid medical formulation according to claim 1, wherein the surfactant is present in a concentration between 0.02 mg/mL and 0.10 mg/mL.

11. (Currently Amended) The ~~stable~~ liquid medical formulation according to claim 1, wherein the antibody against CD40 is a human antibody, a humanized antibody, or a chimeric antibody.

12. (Currently Amended) The ~~stable~~ liquid medical formulation according to claim 1, wherein the antibody against CD40 is a monoclonal antibody.

13. (Currently Amended) The ~~stable~~ liquid medical formulation according to claim 1, wherein the antibody against CD40 is IgG.

14. (Currently Amended) The ~~stable~~ liquid medical formulation according to claim 13, wherein the IgG is any one of IgG1, IgG2, or IgG4.

15-17. (Canceled)

18. (Currently Amended) The ~~stable~~ liquid medical formulation according to claim 1, wherein the antibody against CD40 is present in a concentration between approximately 1 and 200 mg/mL.

19-23. (Canceled)